{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:03:43Z","timestamp":1759341823455,"version":"3.44.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1053\/j.seminhematol.2008.12.001","type":"journal-article","created":{"date-parts":[[2009,2,25]],"date-time":"2009-02-25T04:42:52Z","timestamp":1235536972000},"page":"S37-S43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"S2","title":["Thrombocytopenia in Myelodysplastic Syndromes and Myelofibrosis"],"prefix":"10.1053","volume":"46","author":[{"given":"Adam M.","family":"Boruchov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2008.12.001_bib1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/BF00320305","article-title":"Myelodysplastic syndromes: their history, evolution and relation to acute myeloid leukaemia","volume":"53","author":"Layton","year":"1986","journal-title":"Blut"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib2","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/cncr.22602","article-title":"The incidence and impact of thrombocytopenia in myelodysplastic syndromes","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1634\/theoncologist.8-3-225","article-title":"The forgotten myeloproliferative disorder: myeloid metaplasia","volume":"8","author":"Tefferi","year":"2003","journal-title":"Oncologist"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib4","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1182\/blood-2004-08-3238","article-title":"Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases","volume":"105","author":"Xu","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3109\/10428199509112210","article-title":"Leukemic transformation of primary myelofibrosis: immunophenotype, genotype and growth characteristics of blast cells","volume":"19","author":"Kimura","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.beha.2005.07.008","article-title":"Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options","volume":"19","author":"Mesa","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00277-008-0502-z","article-title":"Myelodysplastic syndromes: molecular pathogenesis and genomic changes","volume":"87","author":"Nolte","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib8","first-page":"71","article-title":"Pathogenesis, etiology and epidemiology of myelodysplastic syndromes","volume":"83","author":"Aul","year":"1998","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib9","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib10","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1365-2362.2004.01417.x","article-title":"Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts","volume":"34","author":"Voulgarelis","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib11","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0145-2126(01)00083-2","article-title":"Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process","volume":"25","author":"Epperson","year":"2001","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib12","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/rheumatology\/keh136","article-title":"Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study","volume":"43","author":"Giannouli","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0609.1995.tb00231.x","article-title":"Immune-mediated complications in patients with myelodysplastic syndromes\u2014clinical and cytogenetic features","volume":"55","author":"Billstrom","year":"1995","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib14","first-page":"893","article-title":"Survival, hospitalization and cause of death in 99 patients with the myelodysplastic syndrome","volume":"9","author":"Konstantopoulos","year":"1989","journal-title":"Anticancer Res"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000107653","article-title":"Defective platelet aggregation in myelodysplastic syndromes","volume":"118","author":"Girtovitis","year":"2007","journal-title":"Acta Haematol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/cyto.b.20163","article-title":"Reticulated platelet counts correlate with treatment response in patients with idiopathic thrombocytopenic purpura and help identify the complex causes of thrombocytopenia in patients after allogeneic hematopoietic stem cell transplantation","volume":"72","author":"Thomas-Kaskel","year":"2007","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib17","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2004-06-2108","article-title":"Increased peripheral platelet destruction and caspase-3-independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients","volume":"105","author":"Houwerzijl","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2141.2007.06776.x","article-title":"Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation","volume":"139","author":"Gupta","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib19","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/ajcp\/98.5.502","article-title":"Refractory thrombocytopenia","volume":"98","author":"Menke","year":"1992","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib20","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/1042819031000063507","article-title":"Clinico-hematologic features of myelodysplastic syndrome presenting as isolated thrombocytopenia: an entity with a relatively favorable prognosis","volume":"44","author":"Sashida","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000064703","article-title":"Unusual myelodysplastic syndrome with the initial presentation mimicking idiopathic thrombocytopenic purpura","volume":"108","author":"Kuroda","year":"2002","journal-title":"Acta Haematol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1046\/j.1365-2141.1996.6322262.x","article-title":"Low incidence of specific anti-platelet antibodies detected by the MAIPA assay in the serum of thrombocytopenic MDS patients and lack of correlation between platelet autoantibodies, platelet lifespan and response to danazol therapy","volume":"94","author":"Hebbar","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2141.2003.03907.x","article-title":"Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes","volume":"120","author":"Bowen","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0140-6736(02)07269-0","article-title":"Treatment of adults with autoimmune thrombocytopenic purpura","volume":"359","author":"Newland","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib25","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/sj.leu.2402129","article-title":"Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases","volume":"15","author":"Bourgeois","year":"2001","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib26","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s00277-005-0003-2","article-title":"Is splenectomy a contraindication for patients with myelodysplastic syndromes complicated by splenomegaly?","volume":"85","author":"Uchida","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib27","first-page":"154","article-title":"The role of splenectomy in children with juvenile myelomonocytic leukemia","volume":"49","author":"Ozyurek","year":"2007","journal-title":"Turk J Pediatr"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib28","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/01.sla.0000143303.10884.58","article-title":"Platelet kinetics and decreased transfusion requirements after splenectomy for hematologic malignancy","volume":"240","author":"Berman","year":"2004","journal-title":"Ann Surg"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib29","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s00277-002-0474-3","article-title":"Splenectomy in patients with mixed myelodysplastic\/myeloproliferative disease","volume":"81","author":"Kraemer","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib30","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood.V90.7.2529","article-title":"Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units","volume":"90","author":"Molldrem","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib31","first-page":"357","article-title":"Combined immunosuppressive treatment in patients with early myelodysplasia [abstract 903]","volume":"90","author":"Cermak","year":"2005","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib32","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.leukres.2004.03.016","article-title":"Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells","volume":"28","author":"Deeg","year":"2004","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.0902-4441.2005.00593.x","article-title":"Cyclosporine-responsive thrombocytopenia in a patient with chloramphenicol-associated myelodysplastic syndrome","volume":"76","author":"Arber","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib34","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000072413","article-title":"Cyclosporine A in the treatment of a patient with immune thrombocytopenia accompanied by myelodysplastic syndrome and nephrotic syndrome","volume":"110","author":"Park","year":"2003","journal-title":"Acta Haematol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib35","first-page":"2654","article-title":"[Immunosuppressive treatment of the myelodysplastic syndrome]","volume":"165","author":"Larsen","year":"2003","journal-title":"Ugeskr Laeger"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib36","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/07357900500283101","article-title":"Immunomodulatory drugs","volume":"23","author":"Crane","year":"2005","journal-title":"Cancer Invest"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib37","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1053\/j.seminoncol.2005.06.018","article-title":"IMiDs: a novel class of immunomodulators","volume":"32","author":"Knight","year":"2005","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib38","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood-2007-01-068833","article-title":"Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q","volume":"111","author":"Raza","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib39","article-title":"A limited number of 5-azacitidine cycles can be effective treatment in MDS","author":"Muller-Thomas","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib40","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib41","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1158\/1078-0432.CCR-04-2135","article-title":"Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes","volume":"11","author":"Kaminskas","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib42","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","article-title":"Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B","volume":"24","author":"Silverman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib43","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/annonc\/mdi007","article-title":"Low-dose interleukin-11 in patients with bone marrow failure: update of the M.D. Anderson Cancer Center experience","volume":"16","author":"Tsimberidou","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib44","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1080\/10428190600758058","article-title":"Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome","volume":"47","author":"Montero","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib45","first-page":"875","article-title":"A phase I\/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia","volume":"22","author":"Nimer","year":"1994","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib46","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1182\/blood.V85.11.3066.bloodjournal85113066","article-title":"A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia","volume":"85","author":"Gordon","year":"1995","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib47","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1046\/j.1365-2141.2000.01916.x","article-title":"Megakaryopoiesis in vitro in myelodysplastic syndromes and acute myeloid leukaemia: effect of pegylated recombinant human megakaryocyte growth and development factor in combination with other growth factors","volume":"108","author":"Liu Yin","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib48","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0145-2126(98)00028-9","article-title":"Analysis of megakaryocyte growth and development factor (thrombopoietin) effects on blast cell and megakaryocyte growth in myelodysplasia","volume":"22","author":"Fontenay-Roupie","year":"1998","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib49","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1182\/blood.V100.10.3457","article-title":"Recombinant human thrombopoietin: basic biology and evaluation of clinical studies","volume":"100","author":"Kuter","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib50","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood.V98.12.3241","article-title":"Thrombocytopenia caused by the development of antibodies to thrombopoietin","volume":"98","author":"Li","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib51","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.V99.7.2599","article-title":"Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor","volume":"99","author":"Basser","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib52","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1182\/asheducation-2007.1.106","article-title":"Novel thrombopoietic agents","author":"Andemariam","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib53","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1182\/blood-2006-10-019315","article-title":"New thrombopoietic growth factors","volume":"109","author":"Kuter","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib54","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cyto.2003.05.001","article-title":"AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl","volume":"25","author":"Broudy","year":"2004","journal-title":"Cytokine"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib55","first-page":"1286","article-title":"Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes","volume":"87","author":"Alessandrino","year":"2002","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib56","doi-asserted-by":"crossref","first-page":"81a","DOI":"10.1182\/blood.V110.11.250.250","article-title":"Phase 1\/2 study of AMG 531 in thrombocytopenic patients (pts) with low-risk myelodysplastic syndrome (MDS): update including extended treatment [abstract 250]","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib57","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/asheducation-2007.1.346","article-title":"Biology and treatment of primary myelofibrosis","author":"Hoffman","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib58","first-page":"1367","article-title":"Myelofibrosis in chronic myeloproliferative disorders\u2014dynamics and clinical impact","volume":"21","author":"Thiele","year":"2006","journal-title":"Histol Histopathol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib59","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00277-005-0042-8","article-title":"Grade of bone marrow fibrosis is associated with relevant hematological findings\u2014a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis","volume":"85","author":"Thiele","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib60","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib61","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000140634","article-title":"JAK2 and MPL mutations in myeloproliferative neoplasms","volume":"119","author":"Koppikar","year":"2008","journal-title":"Acta Haematol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib62","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2141.1981.tb07192.x","article-title":"Idiopathic myelofibrosis: a possible role for immune-complexes in the pathogenesis of bone marrow fibrosis","volume":"49","author":"Cappio","year":"1981","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib63","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1600-0609.1984.tb02189.x","article-title":"Platelet-associated IgG and IgM in myelofibrosis","volume":"32","author":"Hasselbalch","year":"1984","journal-title":"Scand J Haematol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib64","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1600-0609.1985.tb02252.x","article-title":"Circulating immune complexes in myelofibrosis","volume":"34","author":"Hasselbalch","year":"1985","journal-title":"Scand J Haematol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib65","first-page":"69","article-title":"Cellular and molecular mechanisms underlying bone marrow and liver fibrosis: a review","volume":"19","author":"Le Bousse-Kerdiles","year":"2008","journal-title":"Eur Cytokine Netw"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib66","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2141.2007.06807.x","article-title":"Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres","volume":"139","author":"Kuter","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib67","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/10428190801895360","article-title":"JAK and MPL mutations in myeloid malignancies","volume":"49","author":"Tefferi","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib68","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1600-0609.1990.tb00372.x","article-title":"Prognostic factors in idiopathic myelofibrosis: a simple scoring system with prognostic significance","volume":"44","author":"Hasselbalch","year":"1990","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib69","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00005792-198311000-00002","article-title":"The syndrome of idiopathic myelofibrosis","volume":"62","author":"Varki","year":"1983","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib70","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1046\/j.1365-2141.1997.1722990.x","article-title":"Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases","volume":"98","author":"Reilly","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib71","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1002\/cncr.23505","article-title":"Risk factors for leukemic transformation in patients with primary myelofibrosis","volume":"112","author":"Huang","year":"2008","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib72","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3109\/10428190109097709","article-title":"Palliative splenectomy in myelofibrosis with myeloid metaplasia","volume":"42","author":"Mesa","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib73","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/sj.leu.2403875","article-title":"Involvement of transforming growth factor-beta and thrombopoietin in the pathogenesis of myelodysplastic syndrome with myelofibrosis","volume":"19","author":"Akiyama","year":"2005","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib74","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3324\/haematol.12416","article-title":"Low-dose thalidomide in myelofibrosis","volume":"93","author":"Weinkove","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib75","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2004.08.160","article-title":"Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial","volume":"22","author":"Marchetti","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib76","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood-2002-09-2928","article-title":"A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia","volume":"101","author":"Mesa","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib77","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1182\/blood-2006-02-004572","article-title":"Lenalidomide therapy in myelofibrosis with myeloid metaplasia","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib78","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/asheducation-2006.1.233","article-title":"Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders","volume":"510","author":"Levine","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib79","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/sj.leu.2404750","article-title":"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L\/K mutations","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib80","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib81","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/1535-7163.MCT-07-2215","article-title":"LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells","volume":"7","author":"Lipka","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib82","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1182\/blood-2007-04-083402","article-title":"Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2\/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders","volume":"111","author":"Hexner","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib83","first-page":"1037a","article-title":"Phase II study of CEP701, an orally available JAK2 inhibitor, in patients with primary myelofibrosis and post polycythemia vera\/essential thrombocythemia myelofibrosis [abstract 3543]","volume":"110","author":"Verstovsek","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.12.001_bib84","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","article-title":"Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera","volume":"13","author":"Wernig","year":"2008","journal-title":"Cancer Cell"},{"year":"2008","series-title":"JAK-2 abnormalities in the myeloproliferative diseases and their treatment with JAK-2 inhibitors","author":"Silver","key":"10.1053\/j.seminhematol.2008.12.001_bib85"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719630800200X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719630800200X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:19:24Z","timestamp":1758521964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003719630800200X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":85,"alternative-id":["S003719630800200X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2008.12.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombocytopenia in Myelodysplastic Syndromes and Myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2008.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}